Barinthus Biotherapeutics Stock
Barinthus Biotherapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- William James Enright
- Employees
- 14
- Market cap
- $30 M
- IPO
- 30/04/2021
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its…
Barinthus Biotherapeutics stock: price history
1D
+0.0%
1W
+0.0%
1M
+22.9%
6M
+17.5%
YTD
+5.7%
1Y
-33.3%
2Y
-39.8%
5Y
-95.4%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~29% stronger price swings than usual
Ask the agents about Barinthus Biotherapeutics
Analyst assessment of Barinthus Biotherapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 17/11/2025
Barinthus Biotherapeutics stock metrics
P/E
-0.72
P/B
0.53
EV/EBITDA
0.49
RETURN ON EQUITY
-18.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.5%
FLOAT SHARES
39,428,413
AVG. DAILY VOLUME (30D)
57,621
Insider transactions (SEC)
DAWES KAREN A
Enright William
Enright William
Hammacher Alex
Hooftman Leon
Comparable stocks
Frequently asked questions about Barinthus Biotherapeutics stock
What does Barinthus Biotherapeutics do?
Barinthus Biotherapeutics plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is William James Enright, the company employs around 14 people.
The IPO was on 30/04/2021; the stock trades on NASDAQ under the ticker BRNS.
What do analysts say about Barinthus Biotherapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 17/11/2025).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Barinthus Biotherapeutics report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Barinthus Biotherapeutics pay a dividend?
No, Barinthus Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Barinthus Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Barinthus Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Barinthus Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.